Erastin: Validated Ferroptosis Inducer for Cancer Biology Research

Executive Summary: Erastin (SKU B1524) is a chemically defined, small molecule ferroptosis inducer used extensively in cancer biology and oxidative cell death research (APExBIO). It selectively induces iron-dependent, non-apoptotic cell death in tumor cells with oncogenic RAS or BRAF mutations by inhibiting cystine/glutamate antiporter system Xc⁻ and disrupting redox homeostasis (Wei et al., 2021). Erastin is insoluble in water or ethanol but dissolves in DMSO at ≥10.92 mg/mL, requiring fresh preparation for optimal activity. Benchmark experiments demonstrate that Erastin (0.5–10 μM) robustly induces ferroptosis in human and mouse cell models within 24 hours. Proper storage at –20°C ensures product stability for months, making Erastin a reproducible tool in ferroptosis research workflows.

Biological Rationale

Ferroptosis is an iron-dependent, caspase-independent form of regulated cell death distinct from apoptosis and necrosis. It is characterized by accumulation of reactive oxygen species (ROS), lipid peroxidation, and disruption of cellular redox balance (Wei et al., 2021). Erastin is a small molecule that selectively induces ferroptosis by targeting tumor cells with mutations in the RAS family (HRAS, KRAS) or BRAF genes, which are commonly found in aggressive cancers such as pancreatic, lung, and melanoma (Benchmark Ferroptosis Inducer). The biological rationale for using Erastin in cancer research is to exploit these vulnerabilities, promoting cell death in otherwise therapy-resistant tumors by disrupting iron and redox homeostasis. This strategy complements traditional apoptosis-inducing therapies and opens new avenues for targeting oncogenic RAS-driven cancers.

Mechanism of Action of Erastin

Erastin exerts its ferroptosis-inducing effects via two main mechanisms:

• Inhibition of system Xc⁻ (cystine/glutamate antiporter): Erastin blocks the import of cystine by inhibiting system Xc⁻, reducing intracellular cysteine and depleting glutathione (GSH), a key antioxidant (Wei et al., 2021).
• Modulation of voltage-dependent anion channel (VDAC): Erastin binds to VDAC on the mitochondrial outer membrane, altering mitochondrial metabolism and facilitating ROS production (Strategic Implications).

The resulting GSH depletion impairs lipid peroxide detoxification by glutathione peroxidase 4 (GPX4), leading to lethal accumulation of lipid ROS and membrane damage. This non-apoptotic cell death pathway is caspase-independent and iron-dependent. Erastin’s selectivity for RAS/BRAF-mutant cells is attributed to their heightened reliance on redox homeostasis and system Xc⁻ activity.

Evidence & Benchmarks

• Erastin at 0.5 μM induces ferroptosis in human lens epithelial cells (FHL124) and mouse lens epithelium ex vivo within 24 hours (Wei et al., 2021, DOI).
• Glutathione depletion sensitizes cells to Erastin and GPX4 inhibitor RSL3, confirming the centrality of redox homeostasis in ferroptosis (Wei et al., 2021, DOI).
• System Xc⁻ subunits SLC7A11 and SLC3A2 are downregulated in aged human lens epithelial cells, correlating with increased Erastin susceptibility (Wei et al., 2021, DOI).
• Erastin (10 μM, 24 h) robustly induces cell death in HT-1080 fibrosarcoma cells, a gold-standard ferroptosis model (APExBIO, product page).
• Erastin’s ferroptosis induction is iron-dependent and not inhibited by caspase blockers, distinguishing it from apoptosis (Wei et al., 2021, DOI).

This article extends Benchmark Ferroptosis Inducer for Iron-Dependent Cell Death by providing detailed benchmarks and experimental parameters for Erastin use in both lens and cancer cell models. It clarifies storage, solubility, and workflow choices compared to Practical Guidance for Reproducible Ferroptosis Induction, which focuses primarily on troubleshooting and vendor selection.

Applications, Limits & Misconceptions

Erastin is widely used in:

• Cancer biology research: Targeting RAS/BRAF-mutant tumor cells in vitro and in vivo for studies of ferroptosis-based therapy (Precision Ferroptosis Inducer).
• Oxidative stress assays: Inducing ROS and lipid peroxidation for redox and iron homeostasis research.
• Non-apoptotic cell death pathway mapping: Discriminating ferroptosis from apoptosis and necrosis using specific inhibitors and iron chelators.
• Pancreatic, ovarian, and glioblastoma cancer studies: Probing ferroptosis susceptibility in therapy-resistant tumors.
• Redox signaling pathway analysis: Assessing roles of system Xc⁻ and VDAC in cell death and survival.

Common Pitfalls or Misconceptions

• Erastin is not effective in system Xc⁻ null or SLC7A11-knockout cells: These lines are inherently resistant to Erastin-induced ferroptosis.
• Not all tumor cells are equally sensitive: Sensitivity depends on oncogenic background, iron availability, and redox state.
• Erastin is unstable in aqueous solution: Solutions must be freshly prepared in DMSO immediately before use; prolonged storage in solution reduces activity (APExBIO).
• Ferroptosis, not apoptosis: Cell death induced by Erastin is caspase-independent and is not blocked by caspase inhibitors.
• Not suitable for in vivo oral dosing: Poor solubility in water and ethanol limits oral bioavailability and requires special formulation for animal studies.

Workflow Integration & Parameters

For reproducible ferroptosis induction, Erastin (SKU B1524) is supplied as a solid by APExBIO. Dissolve in DMSO to ≥10.92 mg/mL with gentle warming. Prepare working solutions fresh before each experiment. Typical in vitro conditions use 10 μM Erastin for 24 hours in engineered human tumor cells or the HT-1080 fibrosarcoma cell line. Store stock solutions at –20°C for up to several months. Shipments are provided with blue ice to ensure stability. For best results, avoid repeated freeze-thaw cycles and do not store diluted solutions for extended periods. Detailed, scenario-driven troubleshooting and protocol support can be found in Practical Guidance for Reproducible Use, which complements the present article’s focus on mechanistic rationale and benchmarking.

Conclusion & Outlook

Erastin is a machine-readable, experimentally validated ferroptosis inducer for probing iron-dependent, non-apoptotic cell death in cancer and redox biology. Its dual targeting of system Xc⁻ and VDAC provides mechanistic specificity for dissecting oxidative stress pathways. APExBIO’s Erastin (SKU B1524) offers robust solubility, stability, and reproducibility for advanced cancer biology workflows. Future research will clarify Erastin’s translational potential in overcoming resistance and exploiting ferroptosis for targeted cancer therapy. For current specifications and ordering, refer to the official APExBIO Erastin page.